Latest Industry Insights

We spoke with Dr. Christian Dillon to learn more about degradation-based therapies, the challenges associated with their discovery and how innovative solutions are helping to realize the potential of this promising class of therapeutics.

Both genetic and epigenetic sample information is required to get the full picture. Six-base genome sequencing enables this without need of multiple techniques, laborious downstream data processing or data loss, and cancer research is benefiting.

Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development. The three teams will combine data, software and tuned models to develop custom, purpose-built solutions for drug discovery.

In a recent interview, Professor Ulf Landegren shared his perspectives on the future of spatial biology, discussed novel developments in 3D sequencing and outlined why this approach is capturing the attention of researchers worldwide.

Finalists for the New Product Award at the SLAS Europe conference showcase cutting-edge innovations in life sciences, evaluated on technical merit, commercial feasibility, originality, impact and market opportunity. Here, we take a look at the six nominees and the products competing for this year’s award.

At analytica 2024, Technology Networks spoke with Dr. Susanne Soelter, field application specialist at Agilent, to learn more about the impact of PFAS and the challenges that come with PFAS testing.

Bruker Corporation officially opened its new production facility in Bremen – one of Germany’s major science hubs – last week. Technology Networks visited the facility to learn about its low carbon footprint and how it will support Bruker's commitment to innovation and collaboration.

At ELRIG’s Research and Innovation 2024 event, Technology Networks spoke with A4Cell to learn about its SPAchip® technology, which consists of intracellular silicon microchips that monitor cellular pathways in real time.

Sarah Cotts tells us more about the Rheo-Impedance accessory and how it can help overcome limitations with current analysis approaches to improve battery development.

Michelle C. Werner discusses how tRNAs could transform the drug development paradigm from gene-centric to gene-agnostic and accelerate new therapies for 30 million or more patients whose genetically driven disease can be classified under Stop Codon Disease.